Anthem Inc. reported better-than-expected quarterly earnings as its Obamacare individual insurance business broke even and forecast a slight 2018 profit for the government plans despite uncertainty about the market’s future.
The HBA is pleased to announce a new three-part webinar series, Accelerating Gender Intelligence.
A late-stage study shows that a stronger weekly dose of Amgen’s Kyprolis combined with dexamethasone had a greater progression-free survival benefit than a twice-weekly dose of the drug at the approved dosing level.
Despite the failures of late-stage Alzheimer’s drugs developed by numerous companies, Biogen appears confident in the future of the company’s amyloid plaque targeting aducanumab. Biogen announced it had increased its profit potential on the drug by forking over an additional $150 million to Neurimmune Holding AG, the company from which Biogen licensed the drug. Biogen has an option to pay Neurimmune another $50 million to drop royalties by another 5 percent.
The U.S. Food and Drug Administration expanded the approval for Alexion Pharmaceuticals Inc.’s blood-disorder drug and blockbuster medicine Soliris.
Gilead Sciences released results from a Phase II clinical trial of GS-0976 for nonalcoholic steatohepatitis (NASH).
U.S. drugmaker AbbVie is betting on the potential of the body’s immune system to fight Alzheimer’s via a drug development deal worth more than $200 million with unlisted biotech company Alector.
NeuroPace Inc. raised $74 million in equity funding as the medical device maker looks to rapidly expand commercialization of its device to treat epileptic seizures.
The U.S. Food and Drug Administration issued a warning letter to Meridian Bioscience Inc.’s unit for several federal law violations after inspecting its facility that makes lead-testing devices.